301277.SZ
Newland Pharmaceutical Co., Ltd.
SZSE · C 制造业 · CN
CNY 9.34
+1.30%Oct 7, 2026, 08:17 UTC
China’s National Medical Products Administration approved Xintiandi’s marketing application for fondaparinux sodium active pharmaceutical ingredient.
Source:Aug 27, 2026, 08:04 UTC
Xintiandi announced its first-half 2026 results: revenue of 397 million yuan, up 10.64% year-on-year; net profit attributable to shareholders of 60.77 million yuan, down 22.13% year-on-year; and no dividend or share transfer plan.
Source: